GlassScriptPhysician profile
Meera Amar
NPI 1689670184
$8,677.42
in general payments reported to CMS, 2019-2025
60 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $740 · 2021: $1,540 · 2022: $1,044 · 2023: $834 · 2024: $1,346 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608 · Education: $35.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.31 |
| Education | $35.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $976.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $643.21 | 2019-2025 | |
| Novo Nordisk INC | $621.19 | 2019-2025 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $555.08 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $494.86 | 2019-2025 | Korlym |
| Csl Behring | $452.67 | 2019-2024 | Hizentra, Privigen, Haegarda |
| Astrazeneca Pharmaceuticals LP | $402.79 | 2019-2022 | |
| Amarin Pharma, INC. | $306.28 | 2019-2022 | |
| Blueprint Medicines Corporation | $300.71 | 2023-2025 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $243.18 | 2021-2024 | |
| Amgen INC. | $233.12 | 2019-2025 | Tepezza |
| Radius Health, INC. | $196.63 | 2023-2025 | Tymlos |
| Dexcom, INC. | $187.28 | 2020-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $185.53 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $183.83 | 2019-2025 | Eterna, Freestyle Libre 3, Proclaim |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.63 | 2019-2023 | |
| Alk-Abello, INC | $154.13 | 2019-2024 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Mylan Specialty L.P. | $126.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2022-2023 | Nucala |
| Insulet Corporation | $124.74 | 2019-2024 | Omnipod |
| Regeneron Healthcare Solutions, INC. | $118.76 | 2019-2022 | |
| Horizon Therapeutics Plc | $116.97 | 2019-2023 | Tepezza |
| Neurocrine Biosciences, INC. | $111.43 | 2024-2025 | |
| Mannkind Corporation | $92.74 | 2023-2024 | Afrezza |
| Zealand Pharma US, INC. | $89.03 | 2021-2022 | |
| Beta Bionics, INC. | $85.90 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $83.34 | 2025 | Rezdiffra |
| Medtronic, INC. | $81.91 | 2021-2025 | Minimed 780g |
| Shire North American Group INC | $81.83 | 2019 | |
| Cequr Corporation | $78.43 | 2023-2025 | Cequr Simplicity |
| Biocryst US Sales Co., LLC | $77.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $74.46 | 2019-2021 | |
| Averitas Pharma INC. | $73.64 | 2023-2025 | Qutenza |
| Pfizer INC. | $66.33 | 2019-2022 | |
| Kaleo, INC. | $61.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.29 | 2021-2023 | Takhzyro |
| Chiesi USA, INC. | $47.68 | 2024 | Mycapssa |
| Optinose US, INC. | $45.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $41.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.21 | 2025 | |
| Ibsa Pharma INC. | $40.77 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.81 | 2021 | |
| Incyte Corporation | $36.45 | 2021-2025 | Jakafi |
| Intuity Medical INC | $36.37 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Becton, Dickinson and Company | $34.56 | 2021 | |
| Recordati_rare_diseases_inc. | $33.54 | 2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $28.65 | 2020-2025 | Strensiq |
| Valeritas, INC. | $27.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.29 | 2019 | |
| Nevro Corp. | $23.03 | 2024 | Senza |
| Ars Pharmaceuticals Operations, INC. | $21.53 | 2025 | Neffy |
| Ascendis Pharma Endocrinology INC | $21.27 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $20.50 | 2025 | Twiist |
| Kyowa Kirin, INC. | $18.66 | 2024 | Crysvita |
| Companion Medical, INC. | $18.61 | 2019 | |
| Medtronic Minimed, INC. | $17.96 | 2019 | |
| Genentech USA, INC. | $17.71 | 2022 | |
| Esperion Therapeutics, INC. | $13.13 | 2021 | |
| Aytu Biopharma, INC. | $13.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Amar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.